FC
DGX icon

Financial Consulate’s Quest Diagnostics DGX Stock Holding History

Financial Consulate’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12K Hold
10
– – ﹤0.01% 1014
2026
Q1 		$1.96K Buy
10
+2
+25% +$389 ﹤0.01% 986
2025
Q4 		$1.39K Hold
8
– – ﹤0.01% 958
2025
Q3 		$1.52K Buy
+8
New +$1.42K ﹤0.01% 818

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Financial Consulate's DGX Position: Q2 2026 in Review

Financial Consulate held its Quest Diagnostics (DGX) position steady in Q2 2026 at 10 shares worth $2.12K. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

Financial Consulate first reported a position in DGX in Q3 2025 and has held it in 4 quarters since. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Financial Consulate held 10 shares of Quest Diagnostics worth $2.12K as of Q2 2026.
  • Financial Consulate left its Quest Diagnostics share count unchanged in Q2 2026.
  • Quest Diagnostics made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #1014 holding.
  • Financial Consulate first reported a position in Quest Diagnostics in Q3 2025 and has held it in 4 quarters since.
  • 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.